(431p) Micro- and Nano-Particles Developed by Electrohydrodynamic Atomization for the Sustained Delivery of Paclitaxel to Treat C6 Glioma

This study aims to fabricate biodegradable polymeric particles by electrohydrodynamic atomization (EHDA) for applications in sustained delivery of anticancer drug ? paclitaxel to treat C6 glioma. Controllable morphologies such as spheres, donut shape and corrugated shape with sizes from several tens of microns to hundred nanometers of particles were observed by scanning electron microscopy and field emission electron microscope. The differential scanning chromatography study indicated that paclitaxel could be either in an amorphous or disordered-crystalline phase of a molecular dispersion or a solid solution state in the polymer matrix after fabrication. The x-ray photon spectroscopy result suggested that some amount of paclitaxel could exist on the surface layer of the microparticles. The encapsulation efficiency was around 80% and more than 30 days in vitro sustained release profile could be achieved. Cell cycling results suggested that paclitaxel after encapsulation by EHDA could keep its biological function and inhibit C6 glioma cells in the G2/M phase. The cytotoxicity of paclitaxel-loaded biodegradable microparticles to C6 glioma cells could be higher than Taxol® in the long-term in vitro tests evaluated by MTS assay. The in vivo subcutaneous study suggested that 20% drug loading sample could inhibit C6 glioma tumour growth more effectively than Taxol® and there was no evident sign of systemic toxicity. The drug delivery devices developed by EHDA could be promising for the local drug delivery to treat malignant glioma.